19 Octobre 2018 au 23 Octobre 2018

Title: Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

  • Date and time: October 20, 2018, 15:00
  • Presentation number: 1049PD
  • Session: Poster Discussion session – Head and neck
  • Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
  • Location: Hall B3 – Room 23, ICM München, Munich, Germany

Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)

  • Date & time: October 20, 2018, 12:30
  • Presentation number: 1194P
  • Session: Poster Display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259)
  • Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
  • Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany

Title: Changes in the innate immune system as early events in cancer

  • Date & time: October 22, 2018, 15:05 – 15:25
  • Session: Special Symposium Early detection of cancer using minimally invasive biomarkers
  • Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
  • Location: Hall A1 – Room 17, ICM München, Munich, Germany